134 related articles for article (PubMed ID: 18251569)
1. Molecular testing in solid tumors: an overview.
Hunt JL
Arch Pathol Lab Med; 2008 Feb; 132(2):164-7. PubMed ID: 18251569
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.
Aldape K; Burger PC; Perry A
Arch Pathol Lab Med; 2007 Feb; 131(2):242-51. PubMed ID: 17284109
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetic analysis of oligodendroglial tumors.
Hartmann C; Mueller W; Lass U; Kamel-Reid S; von Deimling A
J Neuropathol Exp Neurol; 2005 Jan; 64(1):10-4. PubMed ID: 15715080
[TBL] [Abstract][Full Text] [Related]
4. [The oligodendroglioma: the value of histologic and genetic diagnosis in predicting sensitivity to chemotherapy].
Kros JM
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1379-85. PubMed ID: 15997690
[TBL] [Abstract][Full Text] [Related]
5. Alpha-internexin and altered CIC expression as a supportive diagnostic marker for oligodendroglial tumors with the 1p/19q co-deletion.
Nagaishi M; Suzuki A; Nobusawa S; Yokoo H; Nakazato Y
Brain Tumor Pathol; 2014 Oct; 31(4):257-64. PubMed ID: 24197863
[TBL] [Abstract][Full Text] [Related]
6. Molecular diagnostics of thyroid tumors.
Nikiforov YE
Arch Pathol Lab Med; 2011 May; 135(5):569-77. PubMed ID: 21526955
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathology--translating research into clinical practice: an expanding frontier in surgical oncology.
Nordberg ML
Surg Oncol Clin N Am; 2008 Apr; 17(2):303-21, viii. PubMed ID: 18375354
[TBL] [Abstract][Full Text] [Related]
8. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
9. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
[TBL] [Abstract][Full Text] [Related]
10. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.
Cairncross G; Jenkins R
Cancer J; 2008; 14(6):352-7. PubMed ID: 19060598
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of residual ThinPrep material from thyroid FNAs increases diagnostic sensitivity.
Krane JF; Cibas ES; Alexander EK; Paschke R; Eszlinger M
Cancer Cytopathol; 2015 Jun; 123(6):356-61. PubMed ID: 25926393
[TBL] [Abstract][Full Text] [Related]
12. Unusual thyroid tumors: a review of pathologic and molecular diagnosis.
Hunt JL
Expert Rev Mol Diagn; 2005 Sep; 5(5):725-34. PubMed ID: 16149875
[TBL] [Abstract][Full Text] [Related]
13. Lung adenocarcinoma and its thyroid metastasis characterized on fine-needle aspirates by cytomorphology, immunocytochemistry, and next-generation sequencing.
Bellevicine C; Vigliar E; Malapelle U; Carelli E; Fiorelli A; Vicidomini G; Cappabianca S; Santini M; Troncone G
Diagn Cytopathol; 2015 Jul; 43(7):585-9. PubMed ID: 25900221
[TBL] [Abstract][Full Text] [Related]
14. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology.
Reifenberger G; Louis DN
J Neuropathol Exp Neurol; 2003 Feb; 62(2):111-26. PubMed ID: 12578221
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic and prognostic roles of loss of CIC protein expression in oligodendroglial tumors].
Liu CC; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH; Piao YS
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):679-683. PubMed ID: 29050068
[No Abstract] [Full Text] [Related]
16. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B
Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340
[TBL] [Abstract][Full Text] [Related]
17. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics.
Perry A; Fuller CE; Banerjee R; Brat DJ; Scheithauer BW
Front Biosci; 2003 Jan; 8():a1-9. PubMed ID: 12456321
[TBL] [Abstract][Full Text] [Related]
18. Grade II and III Oligodendroglioma and Astrocytoma.
van den Bent MJ; Chang SM
Neurol Clin; 2018 Aug; 36(3):467-484. PubMed ID: 30072066
[TBL] [Abstract][Full Text] [Related]
19. Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.
Ono T; Reinhardt A; Takahashi M; Nanjo H; Kamataki A; von Deimling A; Shimizu H
Acta Neurochir (Wien); 2020 Dec; 162(12):3019-3024. PubMed ID: 32785787
[TBL] [Abstract][Full Text] [Related]
20. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
